Welcome to our dedicated page for Enveric Biosciences SEC filings (Ticker: ENVB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Enveric Biosciences, Inc. (NASDAQ: ENVB) SEC filings page on Stock Titan centralizes the company’s regulatory disclosures from the U.S. Securities and Exchange Commission. Enveric is a biotechnology company focused on small-molecule neuroplastogenic therapeutics for psychiatric and neurological disorders, and its filings provide detailed information on financing transactions, listing status, governance matters, and risk factors as described by the company.
Investors researching ENVB can use this page to access current reports on Form 8‑K, which Enveric has filed in connection with warrant exercise inducement agreements, private placements of new warrant series, and related use of proceeds for product development, working capital, and general corporate purposes. Other 8‑K filings address Nasdaq listing qualifications, including notices regarding stockholders’ equity requirements, minimum bid price deficiencies, and the implementation of a 1‑for‑12 reverse stock split approved by stockholders and effected through a certificate of amendment.
The filings feed also includes proxy materials such as the definitive proxy statement on Schedule DEF 14A, where Enveric outlines proposals for stockholder approval. These have included authorizations for share issuances related to warrants, reverse stock split ranges, and increases in authorized common stock. Voting results for special meetings and annual meetings are reported in subsequent 8‑K filings, giving readers transparency into stockholder decisions.
Through periodic reports referenced in Enveric’s press releases, such as its Annual Report on Form 10‑K and Quarterly Reports on Form 10‑Q, the company discusses its business, pipeline, patent estate, financial condition, and risk factors. On Stock Titan, users can quickly locate these documents and use AI-powered summaries to interpret complex sections, including descriptions of EB‑003 and other neuroplastogenic programs, capital structure details, and discussions of Nasdaq compliance.
In addition, this page provides access to information about unregistered sales of equity securities, warrant terms, and changes to the company’s charter reported in SEC filings. AI-generated highlights help readers identify key terms—such as exercise prices, expiration dates, and conditions for new warrant series—without manually parsing every exhibit. For those tracking ENVB, the SEC filings page offers a structured way to review how Enveric presents its strategy, financing activities, and governance actions in official regulatory documents.
Enveric Biosciences, Inc. filed an S-3 shelf registration prospectus summarizing the offering structure and administrative details for potential resale of securities. The document includes a table of contents listing standard prospectus sections such as the prospectus summary, risk factors, description of the private placement, use of proceeds, selling stockholders, plan of distribution, legal matters, and incorporation by reference.
A selling-stockholders table lists multiple holders and share counts, with specific examples showing Alto Opportunity Master Fund holding 959,516 shares (with 292,848 offered) and noted percentages such as 2.6% and 1.5% for certain holders. Listed estimated offering expenses show Accountants' fees $12,500, Legal fees $50,000, and Total expenses $62,948.05. The filing is signed by the CEO Joseph Tucker, Ph.D., CFO Kevin Coveney, and multiple directors, all dated September 26, 2025.
Enveric Biosciences, Inc. (ENVB) Schedule 13G filed by Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC reports shared beneficial ownership of warrants and shares following a September 17, 2025 letter agreement with the issuer. After that transaction the Reporting Persons may be deemed to beneficially own 266,668 shares each held by Intracoastal (approximately 5.2% of outstanding common stock based on 5,079,612 shares) if certain warrants were exercisable, but as of the close of business on September 24, 2025 each Reporting Person may be deemed to own 19,333 shares (approximately 0.4%) issuable upon exercise of Intracoastal Warrant 3. Intracoastal Warrant 1 and 2 are not exercisable pending shareholder approval and all three warrants contain blocker provisions limiting exercises above 4.99%.
Enveric Biosciences entered into warrant exercise inducement agreements with institutional investors, leading them to exercise existing Series A and B warrants at a reduced price of $0.915 per share instead of $3.00. This generated approximately $2.2 million in gross cash proceeds before fees. In return, Enveric issued new Series C and Series D warrants covering up to 4,849,996 shares of common stock in total, plus placement agent warrants for up to 169,750 shares, all with specified exercise periods tied to future stockholder approval. The company plans to use the net proceeds for working capital and general corporate purposes and will seek to register the resale of shares underlying the new warrants.
Enveric Biosciences, Inc. filed a current report to announce an operational change and related communication. Effective September 2, 2025, the company changed its principal executive office address to 245 First Street, Riverview II, 18th Floor, Cambridge, MA 02142. The company also furnished a press release as an exhibit, which discusses the same matters under Regulation FD. Enveric’s common stock, with a par value of $0.01 per share, continues to trade on The Nasdaq Stock Market under the symbol ENVB.
Enveric Biosciences, Inc. filed a current report to let investors know that it has prepared an Investor Presentation for Q3 2025. Management plans to post these materials on the company’s website and may use them in discussions with current and potential investors, analysts, lenders, business partners, acquisition candidates, customers, and employees.
The Investor Presentation is furnished as Exhibit 99.1 to this report and is also accessible through Enveric’s investor relations webpage. The company specifies that this information is being “furnished” under Regulation FD, meaning it is not treated as filed for liability purposes under the Exchange Act unless specifically incorporated into another filing.
Enveric Biosciences, Inc. reported that Nasdaq has notified the company it is not meeting the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires at least $2,500,000 of stockholders’ equity, while Enveric’s Form 10-Q for the period ended June 30, 2025, reported stockholders’ equity of $2,184,769.
The company also does not meet Nasdaq’s alternative standards based on market value of listed securities or net income from continuing operations. Enveric has 45 calendar days, until October 10, 2025, to submit a plan to regain compliance, and Nasdaq may grant up to a 180-day extension if the plan is accepted. If the plan is not accepted, Enveric could appeal the determination to a Nasdaq Hearings Panel, and the company states that it intends to submit a compliance plan and monitor its stockholders’ equity.
Enveric Biosciences furnished a press release providing a corporate update and announcing financial results for the quarter ended June 30, 2025, which is attached as Exhibit 99.1 to this Current Report on Form 8-K. The filing also includes a machine-readable Interactive XBRL cover page (Exhibit 104). The Form states the press release and related information are furnished, not filed, and therefore are not subject to Section 18 liability or automatically incorporated by reference into future registration statements except by specific reference.
No numerical financial figures or earnings tables are included in the body of the Form 8-K itself; the substantive financial results are contained in the furnished press release. The filing is signed by Chief Executive Officer Joseph Tucker, Ph.D.